Treatment outcome for NRTI-sparing regimen consisting of dolutegravir and rilpivirine in HIV-1 infected patients
نویسندگان
چکیده
منابع مشابه
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
Current guidelines recommend three drug combinations to treat antiretroviral naïve HIV-infected patients; some data of novel strategies with NRTI-sparing regimen in this setting are now available [1,2]. The study compares immunovirological efficacy and safety of once daily maraviroc (MVC) plus lopinavir/ritonavir (LPV/r) to tenofovir/emtricitabine (TDF/FTC) plus LPV/r. This is an ongoing, proof...
متن کاملPopulation pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
AIM Dolutegravir is the newest integrase inhibitor approved for HIV treatment and has demonstrated potent antiviral activity in patient populations with a broad range of treatment experience. This analysis aimed to characterize the population pharmacokinetics of dolutegravir in treatment-naive patients and to evaluate the influence of patient covariates. METHODS A population pharmacokinetic m...
متن کاملFour-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Aim of this study was to report the 204-week efficacy and safety results of a novel PI- and NRTI-sparing regimen for salvage therapy including maraviroc, raltegravir, etravirine in 28 failing HIV-infected patients with R5-tropic virus. The trend of laboratory parameters was tested by ANOVA for repeated measures and Greenhouse-Geisser probabilities were reported. Results were described as median...
متن کاملNevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
BACKGROUND Nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI)/ritonavir sparing regimens may be useful to some HIV-infected patients. Nevirapine (NVP) and raltegravir (RAL) are both potent antiretrovirals with good long-term safety profiles. METHODS We retrospectively identified from our electronic database all patients with HIV RNA<50 copies/ml for >6 months on an ...
متن کاملRilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
OBJECTIVES In the context of simplification strategies, it is essential to know the feasibility of a switch to a rilpivirine-based therapy. The aim of this study was to describe rilpivirine, tenofovir and emtricitabine resistance in HIV-1-infected patients who experienced virological failure during their previous antiretroviral treatment. PATIENTS AND METHODS The studied population included t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Molecular & Clinical Medicine
سال: 2017
ISSN: 2515-8260
DOI: 10.1016/j.nhccr.2017.06.175